 Connection
Maria Gore to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Maria Gore has written about Diabetes Mellitus, Type 2.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.081 |
|
|
|
-
Gore MO, McGuire DK. A Test in Context: Hemoglobin A1c and Cardiovascular Disease. J Am Coll Cardiol. 2016 Dec 06; 68(22):2479-2486.
Score: 0.190
-
Gore MO, McGuire DK, Lingvay I, Rosenstock J. Predicting cardiovascular risk in type 2 diabetes: the heterogeneity challenges. Curr Cardiol Rep. 2015 Jul; 17(7):607.
Score: 0.172
-
Gore MO, McGuire DK. Drugs for type 2 diabetes mellitus: the imperative for cardiovascular outcome assessment. Diab Vasc Dis Res. 2012 Apr; 9(2):85-8.
Score: 0.137
-
Gore MO, McGuire DK. Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments. Eur Heart J. 2011 Aug; 32(15):1832-4.
Score: 0.128
-
Gore MO, McGuire DK. Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs. Curr Cardiol Rep. 2009 Jul; 11(4):258-63.
Score: 0.113
-
Gore MO, McGuire DK. The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context. Diab Vasc Dis Res. 2009 Jan; 6(1):53-5.
Score: 0.110
-
Salahuddin UI, Pandey A, Ayers CR, See R, Neeland IJ, Gore MO, Grinsfelder DB, Abdullah SM, Khera A, de Lemos JA, McGuire DK. Effect of treatment with rosiglitazone on high-sensitivity cardiac troponin levels among patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016 Mar; 13(2):113-8.
Score: 0.044
-
Sénéchal M, Ayers CR, Szczepaniak LS, Gore MO, See R, Abdullah SM, Berry JD, McGuire DK, McGavock JM. Is cardiorespiratory fitness a determinant of cardiomyopathy in the setting of type 2 diabetes? Diab Vasc Dis Res. 2014 Sep; 11(5):343-51.
Score: 0.040
-
McGavock J, Szczepaniak LS, Ayers CR, Abdullah SM, See R, Gore MO, Drazner MH, de Lemos JA, McGuire DK. The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: a randomised, placebo-controlled trial. Diab Vasc Dis Res. 2012 Apr; 9(2):131-7.
Score: 0.033
-
Hamilton MP, Gore MO, Ayers CR, McGuire DK, Scherer PE. Adiponectin and cardiovascular risk profile in patients with type 2 diabetes mellitus: parameters associated with adiponectin complex distribution. Diab Vasc Dis Res. 2011 Jul; 8(3):190-4.
Score: 0.032
-
Narang N, Armstead SI, Stream A, Abdullah SM, See R, Snell PG, McGavock J, Ayers CR, Gore MO, Khera A, de Lemos JA, McGuire DK. Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment. Diab Vasc Dis Res. 2011 Apr; 8(2):101-8.
Score: 0.032
-
McGuire DK, Gore MO, Masoudi FA. Diabetes and heart failure in patients with coronary disease: separating markers from mediators. Diabetes Care. 2010 Sep; 33(9):2120-2.
Score: 0.031
-
Gada E, Owens AW, Gore MO, See R, Abdullah SM, Ayers CR, Rohatgi A, Khera A, de Lemos JA, McGuire DK. Discordant effects of rosiglitazone on novel inflammatory biomarkers. Am Heart J. 2013 Apr; 165(4):609-14.
Score: 0.009
-
Narang N, Gore MO, Snell PG, Ayers CR, Lorenzo S, Carrick-Ranson G, Babb TG, Levine BD, Khera A, de Lemos JA, McGuire DK. Accuracy of estimating resting oxygen uptake and implications for hemodynamic assessment. Am J Cardiol. 2012 Feb 15; 109(4):594-8.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|